LPR is estimated to affect more than 20% of the United States population.
N-Zyme Biomedical seeks to provide a much-needed treatment for the millions of people in the US and worldwide that suffer from LPR.
The disclosure provides a composition comprising an inhaled formulation of an HIV protease inhibitor capable of inhibiting pepsin and a pharmaceutically acceptable carrier.» Request Investor Presentation for details
Founded by Franco Vigile, an enterpreneur, and Nikki Johnston, Ph.D., who dedicated her career to LPR research.» Meet our team
The Medical College of Wisconsin received a "Study May Proceed" letter from The Center for Drug Evaluation and Research in the FDA approving their IND 149546 to assess the efficacy of fosamprenavir/Lexiva for the treatment of LPR in a phase III clinical trial.
The Medical College of Wisconsin Institutional Review Board (IRB) has approved the 12-week randomized, double-blinded, placebo-controlled clinical trial to assess the efficacy of fosamprenavir/Lexiva for LPR, Protocol ID: PRO00037954.
International Patent Application: PCT/US2021/027758, Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux, was filed by the Medical College of Wisconsin on April 16, 2021. Nikki Johnston is the sole named inventor on that patent. Claims include use of HIV inhibitors for reflux (LPR, GERD, and airway reflux), by both local/inhaled and oral/systemic delivery.